227 related articles for article (PubMed ID: 15090572)
1. Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument.
Müller J; Wissel J; Kemmler G; Voller B; Bodner T; Schneider A; Wenning GK; Poewe W
J Neurol Neurosurg Psychiatry; 2004 May; 75(5):749-53. PubMed ID: 15090572
[TBL] [Abstract][Full Text] [Related]
2. Quality of life in patients with craniocervical dystonia: Italian validation of the "Cervical Dystonia Impact Profile (CDIP-58)" and the "Craniocervical Dystonia Questionnaire (CDQ-24)".
Fabbri M; Superbo M; Defazio G; Scaglione CL; Antelmi E; Basini G; Nassetti S; Pizza F; Plasmati R; Liguori R
Neurol Sci; 2014 Jul; 35(7):1053-8. PubMed ID: 24477322
[TBL] [Abstract][Full Text] [Related]
3. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression.
Müller J; Kemmler G; Wissel J; Schneider A; Voller B; Grossmann J; Diez J; Homann N; Wenning GK; Schnider P; Poewe W;
J Neurol; 2002 Jul; 249(7):842-6. PubMed ID: 12140667
[TBL] [Abstract][Full Text] [Related]
4. Craniocervical Dystonia Questionnaire (CDQ-24): validation and cross-cultural adaptation in Serbian patients.
Tepavcević DK; Svetel M; Pekmezović T; Petrović I; Kostić VS
Coll Antropol; 2009 Dec; 33(4):1185-9. PubMed ID: 20102067
[TBL] [Abstract][Full Text] [Related]
5. Validation of the Turkish version of the Celiac Disease Questionnaire (CDQ).
Aksan A; Mercanlıgil SM; Häuser W; Karaismailoğlu E
Health Qual Life Outcomes; 2015 Jun; 13():82. PubMed ID: 26088079
[TBL] [Abstract][Full Text] [Related]
6. Quality of life in long-term botulinum toxin treatment of cervical dystonia: Results of a cross sectional study.
Moll M; Rosenthal D; Hefter H
Parkinsonism Relat Disord; 2018 Dec; 57():63-67. PubMed ID: 30150129
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of the Celiac Disease Questionnaire (CDQ), a disease-specific health-related quality of life measure for adult patients with celiac disease.
Häuser W; Gold J; Stallmach A; Caspary WF; Stein J
J Clin Gastroenterol; 2007 Feb; 41(2):157-66. PubMed ID: 17245214
[TBL] [Abstract][Full Text] [Related]
8. Impact of Neu-botulinumtoxinA on the Severity and Quality of Life of Cervical Dystonia Patients.
Jagota P; Kaewwilai L; Boonrod N; Singmaneesakulchai S; Boonpang K; Sringean J; Jitkritsadakul O; Petchrutchatachart S
Tremor Other Hyperkinet Mov (N Y); 2016; 6():407. PubMed ID: 27536464
[TBL] [Abstract][Full Text] [Related]
9. The physical, social and emotional aspects are the most affected in the quality of life of the patients with cervical dystonia.
Werle RW; Takeda SY; Zonta MB; Guimarães AT; Teive HA
Arq Neuropsiquiatr; 2014 Jun; 72(6):405-10. PubMed ID: 24964104
[TBL] [Abstract][Full Text] [Related]
10. Quality of life in cervical dystonia after treatment with botulinum toxin A: a 24-week prospective study.
Kongsaengdao S; Maneeton B; Maneeton N
Neuropsychiatr Dis Treat; 2017; 13():127-132. PubMed ID: 28138245
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Specialized Physical Therapy in Cervical Dystonia: Outcomes of a Randomized Controlled Trial.
van den Dool J; Visser B; Koelman JH; Engelbert RH; Tijssen MA
Arch Phys Med Rehabil; 2019 Aug; 100(8):1417-1425. PubMed ID: 30796919
[TBL] [Abstract][Full Text] [Related]
12. Validation of a French version of the quality of life "Celiac Disease Questionnaire".
Pouchot J; Despujol C; Malamut G; Ecosse E; Coste J; Cellier C
PLoS One; 2014; 9(5):e96346. PubMed ID: 24788794
[TBL] [Abstract][Full Text] [Related]
13. Cervical dystonia and quality of life.
Tomic S; Petkovic I; Pucic T; Resan B; Juric S; Rotim T
Acta Neurol Belg; 2016 Dec; 116(4):589-592. PubMed ID: 27138215
[TBL] [Abstract][Full Text] [Related]
14. An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport).
Hefter H; Benecke R; Erbguth F; Jost W; Reichel G; Wissel J
BMJ Open; 2013; 3(4):. PubMed ID: 23604344
[TBL] [Abstract][Full Text] [Related]
15. Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting.
Dowson AJ; Kilminster SG; Salt R
Drugs R D; 2008; 9(3):147-58. PubMed ID: 18457467
[TBL] [Abstract][Full Text] [Related]
16. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study.
Rollnik JD; Matzke M; Wohlfarth K; Dengler R; Bigalke H
Eur Neurol; 2000; 43(1):9-12. PubMed ID: 10601802
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm.
Ochudlo S; Bryniarski P; Opala G
Parkinsonism Relat Disord; 2007 Dec; 13(8):505-8. PubMed ID: 17543569
[TBL] [Abstract][Full Text] [Related]
18. The development and validation of the Cluster Headache Quality of life scale (CHQ).
Abu Bakar N; Torkamani M; Tanprawate S; Lambru G; Matharu M; Jahanshahi M
J Headache Pain; 2016 Dec; 17(1):79. PubMed ID: 27596922
[TBL] [Abstract][Full Text] [Related]
19. Quality of life in patients with focal dystonia.
Pekmezovic T; Svetel M; Ivanovic N; Dragasevic N; Petrovic I; Tepavcevic DK; Kostic VS
Clin Neurol Neurosurg; 2009 Feb; 111(2):161-4. PubMed ID: 18995953
[TBL] [Abstract][Full Text] [Related]
20. Translation, adaptation, and cross-cultural validation of the CDQ-24 scale in patients with primary blepharospasm under botulinum toxin treatment, pilot test.
Mejia-Vergara AJ; Méndez Cardona L; Flórez Rocha DA; Rozo N; Rincón López JV
Arch Soc Esp Oftalmol (Engl Ed); 2024 Jun; ():. PubMed ID: 38878820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
